Suramin inhibits macrophage activation by human group IIA phospholipase A2, but does not affect bactericidal activity of the enzyme
暂无分享,去创建一个
[1] R. Ward,et al. Insights on calcium-independent phospholipid membrane damage by Lys49-PLA2 using tryptophan scanning mutagenesis of bothropstoxin-I from Bothrops jararacussu. , 2008, Biochimie.
[2] M. Teresa Pisabarro,et al. Mechanism of inhibition of human secretory phospholipase A2 by flavonoids: rationale for lead design , 2007, J. Comput. Aided Mol. Des..
[3] R. Ward,et al. Mapping of the structural determinants of artificial and biological membrane damaging activities of a Lys49 phospholipase A2 by scanning alanine mutagenesis. , 2007, Biochimica et biophysica acta.
[4] R. Stábeli,et al. Snake venom phospholipase A2 inhibitors: medicinal chemistry and therapeutic potential. , 2007, Current topics in medicinal chemistry.
[5] R. Arni,et al. Interfacial surface charge and free accessibility to the PLA2-active site-like region are essential requirements for the activity of Lys49 PLA2 homologues. , 2007, Toxicon : official journal of the International Society on Toxinology.
[6] H. Buhr,et al. Suramin Inhibits Not Only Tumor Growth and Metastasis but Also Angiogenesis in Experimental Pancreatic Cancer , 2007, Journal of Gastrointestinal Surgery.
[7] M. Gelb,et al. Secreted phospholipase A2 inhibitors are also potent blockers of binding to the M-type receptor. , 2006, Biochemistry.
[8] Edward A Dennis,et al. The phospholipase A2 superfamily and its group numbering system. , 2006, Biochimica et biophysica acta.
[9] M. Triggiani,et al. Activation of human inflammatory cells by secreted phospholipases A2. , 2006, Biochimica et biophysica acta.
[10] Chien-Huang Lin,et al. Lipoteichoic acid-induced nitric oxide synthase expression in RAW 264.7 macrophages is mediated by cyclooxygenase-2, prostaglandin E2, protein kinase A, p38 MAPK, and nuclear factor-kappaB pathways. , 2006, Cellular signalling.
[11] W. Shafer,et al. Antimicrobial peptides and endotoxin inhibit cytokine and nitric oxide release but amplify respiratory burst response in human and murine macrophages , 2005, Cellular microbiology.
[12] J. Au,et al. Nontoxic Suramin Treatments Enhance Docetaxel Activity in Chemotherapy-Pretreated Non-Small Cell Lung Xenograft Tumors , 2005, Pharmaceutical Research.
[13] R. Arni,et al. Inhibition of myotoxic activity of Bothrops asper myotoxin II by the anti-trypanosomal drug suramin. , 2005, Journal of molecular biology.
[14] Shi-bo Tang,et al. [The inhibiting effects of suramin on bFGF induced proliferation of cultured human RPE cells]. , 2005, [Zhonghua yan ke za zhi] Chinese journal of ophthalmology.
[15] J. Holland,et al. Quality of life impact of three different doses of suramin in patients with metastatic hormone‐refractory prostate carcinoma , 2004, Cancer.
[16] C. Suschek,et al. The role of iNOS in chronic inflammatory processes in vivo: is it damage-promoting, protective, or active at all? , 2004, Current molecular medicine.
[17] R. Ward,et al. Topology of the substrate-binding site of a Lys49-phospholipase A2 influences Ca2+-independent membrane-damaging activity. , 2004, The Biochemical journal.
[18] M. Gallacci,et al. Antagonism of myotoxic and paralyzing activities of bothropstoxin-I by suramin. , 2003, Toxicon : official journal of the International Society on Toxinology.
[19] M. Gelb,et al. Interfacial Kinetic and Binding Properties of the Complete Set of Human and Mouse Groups I, II, V, X, and XII Secreted Phospholipases A2 * , 2002, The Journal of Biological Chemistry.
[20] J. Balsinde,et al. Phospholipase A2 regulation of arachidonic acid mobilization , 2002, FEBS letters.
[21] C. Betzel,et al. Design of specific peptide inhibitors of phospholipase A2: structure of a complex formed between Russell's viper phospholipase A2 and a designed peptide Leu-Ala-Ile-Tyr-Ser (LAIYS). , 2002, Acta crystallographica. Section D, Biological crystallography.
[22] C. Betzel,et al. First structural evidence of a specific inhibition of phospholipase A2 by alpha-tocopherol (vitamin E) and its implications in inflammation: crystal structure of the complex formed between phospholipase A2 and alpha-tocopherol at 1.8 A resolution. , 2002, Journal of molecular biology.
[23] P. A. Melo,et al. Effect of suramin on myotoxicity of some crotalid snake venoms. , 2002, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[24] M. Gelb,et al. The Antibacterial Properties of Secreted Phospholipases A2 , 2002, The Journal of Biological Chemistry.
[25] J. Lim,et al. Group IIA secretory phospholipase A2 stimulates inducible nitric oxide synthase expression via ERK and NF‐κB in macrophages , 2001, European journal of immunology.
[26] W. B. Church,et al. A Novel Approach to the Design of Inhibitors of Human Secreted Phospholipase A2 Based on Native Peptide Inhibition* 210 , 2001, The Journal of Biological Chemistry.
[27] R. Ward,et al. Refolding and purification of Bothropstoxin-I, a Lys49-phospholipase A2 homologue, expressed as inclusion bodies in Escherichia coli. , 2001, Protein expression and purification.
[28] D. Wilton,et al. The antibacterial properties of secreted phospholipases A(2). , 2000, Biochimica et biophysica acta.
[29] A. Rademaker,et al. A Pilot Trial of Suramin in Metastatic Breast Cancer to Assess Antiangiogenic Activity in Individual Patients , 2000, Oncology.
[30] D. J. Mason,et al. Flow Cytometric Monitoring of Antibiotic-Induced Injury in Escherichia coli Using Cell-Impermeant Fluorescent Probes , 2000, Antimicrobial Agents and Chemotherapy.
[31] R. Schevitz,et al. Structure-based design of a new class of anti-inflammatory drugs: Secretory phospholipase A2 inhibitors, SPI , 1999 .
[32] S. Lin-Shiau,et al. Suramin inhibits the toxic effects of presynaptic neurotoxins at the mouse motor nerve terminals. , 1999, European journal of pharmacology.
[33] T. Nevalainen,et al. Protection by group II phospholipase A2 against Staphylococcus aureus. , 1999, Journal of immunology.
[34] M. Freissmuth,et al. G protein antagonists. , 1999, Trends in pharmacological sciences.
[35] A. Kleinfeld,et al. The measurement of free fatty acid concentration with the fluorescent probe ADIFAB: A practical guide for the use of the ADIFAB probe , 1999, Molecular and Cellular Biochemistry.
[36] R. Othman,et al. Tryptophan-containing mutant of human (group IIa) secreted phospholipase A2 has a dramatically increased ability to hydrolyze phosphatidylcholine vesicles and cell membranes. , 1998, Biochemistry.
[37] R. Lehrer,et al. Secretory Phospholipase A2 Is the Principal Bactericide for Staphylococci and Other Gram-Positive Bacteria in Human Tears , 1998, Infection and Immunity.
[38] Y. Snitko,et al. High specificity of human secretory class II phospholipase A2 for phosphatidic acid. , 1997, The Biochemical journal.
[39] R. Othman,et al. Human non-pancreatic (group II) secreted phospholipase A2 expressed from a synthetic gene in Escherichia coli: characterisation of N-terminal mutants. , 1996, Biochimica et biophysica acta.
[40] A. IJzerman,et al. Suramin analogues as subtype-selective G protein inhibitors. , 1996, Molecular pharmacology.
[41] M. Lazdunski,et al. Identification of the Binding Domain for Secretory Phospholipases A2 on Their M-type 180-kDa Membrane Receptor * , 1995, The Journal of Biological Chemistry.
[42] M. Díaz-Guerra,et al. Bacterial Lipopeptides Induce Nitric Oxide Synthase and Promote Apoptosis through Nitric Oxide-independent Pathways in Rat Macrophages (*) , 1995, The Journal of Biological Chemistry.
[43] R. Lehrer,et al. Bactericidal properties of murine intestinal phospholipase A2. , 1995, The Journal of clinical investigation.
[44] J. J. Rosa,et al. Structures of free and inhibited human secretory phospholipase A2 from inflammatory exudate. , 1993, Science.
[45] I. Coppens,et al. The uptake of the trypanocidal drug suramin in combination with low-density lipoproteins by Trypanosoma brucei and its possible mode of action. , 1993, Acta tropica.
[46] T. Lane,et al. Gamma interferon cooperates with lipopolysaccharide to activate mouse splenic macrophages to an antihistoplasma state , 1993, Infection and immunity.
[47] L. Packer,et al. Tocopherol analogs suppress arachidonic acid metabolism via phospholipase inhibition. , 1992, The Journal of biological chemistry.
[48] C. Stoner,et al. Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. , 1991, The Journal of biological chemistry.
[49] W. Ripka,et al. Molecular modeling in the design of phospholipase A2 inhibitors , 1989, Journal of cellular biochemistry.
[50] T. Mosmann. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.
[51] H. Kihara. Studies on phospholipase A in Trimeresurus flaoviridis venom. III. Purification and some properties of phospholipase A inhibitor in Habu serum. , 1976, Journal of biochemistry.
[52] J. Vidal,et al. Zymogen-catalyzed hydrolysis of monomeric substrates and the presence of a recognition site for lipid-water interfaces in phospholipase A2. , 1974, Biochemistry.
[53] S. Jancar,et al. Immune complex-mediated tissue injury: a multistep paradigm. , 2005, Trends in immunology.
[54] Robert,et al. Induction of Phospholipase A 2 Gene Expression in Human Hepatoma Cells by Mediators of the Acute Phase Response * , 2001 .
[55] M. Pintore,et al. A molecular modeling and 3D QSAR study of a large series of indole inhibitors of human non-pancreatic secretory phospholipase A2. , 2001, European journal of medicinal chemistry.
[56] R. Schevitz,et al. Structure-based design of a new class of anti-inflammatory drugs: secretory phospholipase A(2) inhibitors, SPI. , 1999, Biochimica et biophysica acta.
[57] C. Nathan,et al. Nitric oxide and macrophage function. , 1997, Annual review of immunology.
[58] M. Christian,et al. New drugs in non-Hodgkin's lymphoma. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[59] G. Atsumi,et al. Regulatory functions of phospholipase A2. , 1997, Critical reviews in immunology.
[60] J. Browning,et al. Extracellular phospholipase A2 expression and inflammation: the relationship with associated disease states. , 1993, Journal of lipid mediators.
[61] D. Jodrell,et al. Suramin, an active drug for prostate cancer: interim observations in a phase I trial. , 1993, Journal of the National Cancer Institute.
[62] L. M. Deenen,et al. THE SUBSTRATE SPECIFICITY OF PHOSPHOLIPASE A. , 1963 .
[63] J. Schneider. [Treatment of human African trypanosomiasis]. , 1963, Bulletin of the World Health Organization.